Janssen’s Carvykti (cilta-cel) FDA approval sets the pace for a cell therapy race in multiple myeloma

Posted on Mar 1, 2022

Second-to-market Carvykti is expected to overtake BMS’ Abecma by 2023 due to a stronger clinical profile.

The FDA has approved Janssen’s and Legend Biotech’s BCMA-targeting CAR T-cell therapy Carvykti (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with RRMM after four or more prior lines of therapy, on its target date of February 28, 2022, after a three-month PDUFA resolution.

Carvykti is the second CAR T approved for the treatment of multiple myeloma, following BMS’ and 2seventy bio’s Abecma (idecabtagene vicleucel; ide-cel) FDA approval in March 2021. Both assets target BCMA, share the same indication and are available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS).

Carvykti’s approval is based on data from the pivotal Phase I/II CARTITUDE-1 study (NCT03548207) with a 97.9% ORR, at a median of 18 months follow-up. Carvykti is superior to Abecma in terms of efficacy but exhibits a higher incidence of CRS, grade 3/4 neutropenia, and CAR-T cell-related neurotoxicity compared to Abecma.

Manufacturing challenges have been severely affecting Abecma’s supply. Janssen and Legend Biotech are addressing that by activating a limited network of certified treatment centres to scale its production capacity throughout the US in 2022.

Our market share uptake simulation places Carvykti in a strong position upon entry compared to Abecma, based on Carvykti’s greater clinical responses and reflected in positive KOL sentiment. In the launch year we expect Carvykti to hold 7.1% market share in 4L+ increasing to 12.9% at peak share in 2023 (annual revenue estimated at $365 million). From 2023 we expect Carvykti market share to drop due to the entry of “off-the-shelf” BCMAxCD3 bispecific antibodies, which boast impressive efficacy and lower incidence of neurotoxicities.

Source(s): Janssen Carvykti Approval Press Release; Abecma Cost; Abecma FDA label; Abecma REMS; EndpointsNews; Airfinity 

For more information about Airfinity's analytics and predictive capabilities in Multiple Myeloma and beyond, contact the team here.

More Insights From Airfinity

Introducing Airfinity Biorisk: Risk Surveillance and Analytics for 160+ Infectious Diseases

Oct 10, 2022

18 million monkeypox vaccines needed to protect most at risk, 85 million to protect wider gay community and health workers

Aug 25, 2022

Sales of COVID-19 antiviral pill Paxlovid to leap frog Merck’s competitor Molnupiravir

Jul 25, 2022

COVID-19 vaccines sales to bounce back with new jabs taking a fifth of the 2022 market

Jul 15, 2022

AstraZeneca and Pfizer/BioNTech saved over 12 million lives in the first year of vaccination

Jul 13, 2022

Global wastage of COVID-19 vaccines could be 1.1 billion doses

Jul 11, 2022